Cocrystal Pharma Inc (OTCBB:COCP) is a small cap firm that has witnessed transformative merger last year. It focuses on developing innovative medications for the treatment of human viral diseases such as Hepatitis C, influenza, norovirus and others. The company’s recent merger with RFS Pharma expands expert team by including Dr. Ray Schinazi, who was a founder of Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Triangle Pharmaceuticals and Pharmasset. He still continues to work on the state-of-the-art pan-genotypic Hepatitis C therapy.
Cocrystal and RFS merged to form an advanced antiviral development company. RFS Pharma was a privately owned biotech firm established by famous drug developer, Dr. Schinazi. Since 2004, the company has been working to develop innovative treatments for human viral diseases. After merger, shareholders of RFS Pharma and Cocrystal Pharma Inc (OTCBB:COCP) owned almost 50%of the combined entity on a fully diluted basis.
The expert view
Dr, Schinazi stated that the merger with Cocrystal will produce considerable advances in research productivity and innovation. The two companies will be in a better position to extend their product portfolio. The technology and skill set that the team of Cocrystal brings to a new entity is synergistic with RFS Pharma’s plans. Together, the two companies will be able to develop as a company that can pace up progress of drug approval for novel treatments meant for serious viral diseases.
The management view
The management of Cocrystal Pharma Inc (OTCBB:COCP) stated that the merger provides a strong platform to both companies individual’s strength. It will increase the chances of developing superior treatments for major viral infections. The strategic benefits will enhance the value of product portfolio. Dr. Schinazi is a prominent name in nucleoside chemistry and biology and is also the founder of a number of successful biotech companies. The directors of the new entity are Gary Wilcox, Philip Frost, Steven D. Rubin, David Block, Jane Hsiao, Dr. Schinazi and Jeffrey Meckler.